NCT01567683已完成1 期
A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
This study is designed to assess the tolerability of test product and vehicle in terms of skin reactions during repeated topical applications on healthy skin under controlled conditions on the basis of the international guidelines for testing of skin irritations (FDA Guidance for Industry (1999)).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The written informed consent form (ICF) signed and dated by the subject prior to any study-related activity
- •Generally healthy male or female subjects aged ≥ 18 years
- •Healthy skin in the treatment areas (inner site of forearms) and test field for positive control on the upper arm
- •Skin type I-III (Fitzpatrick)
- •Willingness to actively participate in the study and to comply with the study procedures as defined in the study protocol
- •High probability of a good compliance and orderly completion of the study
- •Female subjects of childbearing potential must use a highly effective method of contraception
- •Negative urine pregnancy test (in female subjects with childbearing potential)
排除标准
- •Pregnant or breast-feeding women
- •Known or suspected skin diseases (e.g. acne vulgaris, atopic dermatitis, psoriasis, etc.), which might interfere with the evaluation of the skin reaction at the treatment area or the SLS test field
- •Clinical history suggestive of intolerance, allergies or idiosyncrasies to one of the IMPs or to the ingredients of the products (butyl lactate, isopropyl myristate, propylene glycol, butylated hydroxy anisole) and suspected cross allergies
- •Known skin allergies
- •Known infectious diseases (e.g. HIV, hepatitis) at the discretion of the investigator
- •Insulin dependent diabetes
- •Psychiatric conditions that might limit the participation in the trial and / or that lead to the assumption that the ability to completely understand the consequences of consent is missing
- •Any suspicion of drug and / or alcohol abuse within the past 5 years
- •Any illness or circumstance that could affect the trial purpose in the opinion of the investigator
- •Within 1 week prior to Day 1 and during the whole study any systemic use of antihistamines
- •Within 4 weeks prior to Day 1 and during the entire study no change in any medication with common medical influence on skin perfusion (e.g. beta-blockers)
- •Within 4 weeks prior to Day 1 and during the entire trial any use of systemic medication likely to interfere with the trial purposes (e.g. immune-modulating therapy, corticosteroids, cytotoxics or immunosuppressants)
- •Within 2 weeks prior to Day 1 and during the entire trial: any dermatological medication (drug or medical device) on treatment areas or SLS test field (exceptions: symptomatic treatment of discontinued areas with topical treatments as decided by the investigator)
- •Use of cosmetic product (e.g. creams, moisturizers) in the treatment areas (i.e. inner forearms) or the SLS test field within 5 days prior to Day 1 and throughout the treatment phase (Day 1 to Day 22)
- •Intensive UV-light exposure (e.g. solarium visits) within 4 weeks before Day 1 as well as during the study
- •Moles, tattoos, pigmentation or scars in the application areas (arms) that would influence the visual scoring
- •Participation in another clinical trial within 30 days directly preceding the study, during the entire study, and earlier participation in this study
- •Employees of the study site or of the Sponsor's company
研究组 & 干预措施
Limtop solution (imiquimod), Vehicle solution for topical use
Experimental
干预措施: Imiquimod (topical use) (Drug)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Evaluate the Safety, Local and Systemic Tolerability, and Pharmacokinetics of Multiple-Dose Topical Administration of PF-07038124 in Japanese Healthy ParticipantsHealthyNCT04863417Pfizer12
招募中
不适用
Double-blinded, Vehicle Controlled Study to Evaluate Efficacy & Tolerance of Bakuchiol and Ethyl Linoleate on AcneAcne VulgarisNCT05069272Ratan K. Chaudhuri40
已完成
1 期
Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)Wound HealingCicatrixNCT00978302Renovo55
终止
4 期
Tolerance Study of the Silicone Bands on Medical Compression StockingsSkin LesionsNCT01486225Laboratoires Innothera3
已完成
不适用
To Check Dermatological Safety of Test Products by 24 Hours Patch Test on Adult Healthy Human Subjects.Normal SkinNCT06631898NovoBliss Research Pvt Ltd26